Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | NMBR | P28336 | 1/20 | 0.38 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.38 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6182341 | 0.77 | NMBR (0.39) | NMBRKDM4E | |
| SCHEMBL6183629 | 0.73 | NMBR (0.39) | KMT2ANMBR | |
| SCHEMBL6184297 | 0.73 | NMBR (0.40) | NMBR | |
| SCHEMBL6182145 | 0.72 | NMBR (0.39) | NMBR | |
| SCHEMBL6802108 | 0.69 | NMBR (0.42) | MEN1KMT2ATDP1NMBRSOAT1 | |
| SCHEMBL3412535 | 0.63 | NMBR (0.48) | KMT2ANMBREPHX2 | |
| SCHEMBL3409677 | 0.62 | NMBR (0.49) | NMBRSOAT1SOAT2EPHX2 | |
| SCHEMBL6181051 | 0.62 | NMBR (0.53) | NMBR | |
| SCHEMBL6182113 | 0.62 | NMBR (0.50) | NMBR | |
| SCHEMBL6183997 | 0.62 | NMBR (0.41) | MEN1KMT2ATDP1NMBRSOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | MEN1 368/4885KMT2A 3959/4885TDP1 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.